Skip to main content

Advertisement

Table 5 Main and secondary outcomes for medicine groups at six week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable Mebeverine Methylcellulose Placebo Significance
IBS-SSS total mean (n = 123) 183.3 (156.9-209.7) 174.0 (149.7-198.4) 210.6 (185.6-235.5) p = 0.106
IBS-QOL score (n = 123) 69.5 (65.7-73.4) 69.4 (65.8-73.0) 69.7 (66.0-73.3) p = 0.994
HADS score for anxiety (n = 114) 8.7 (7.7-9.7) 9.0 (8.1-9.9) 9.2 (8.3-10.1) p = 0.743
HADS score for depression (n = 114) (%)     p = 0.590
Normal (0–7) 29 (30.9) 36 (38.3) 29 (30.9)  
Mild (8–10) 3 (16.7) 5 (27.8) 10 (55.6)  
Moderate or Severe (11–21) 2 (40.0) 0 (0) 3 (60.0)  
Enablement score (n = 113)     p = 0.563
0 6 (19.4) 14 (35.9) 12 (27.9)  
1-2 5 (16.1) 6 (15.4) 5 (11.6)  
3-5 9 (29.0) 11 (28.2) 15 (34.9)  
6-12 11 (35.5) 8 (20.5) 11 (25.6)  
  1. Analysis of the 6 week follow-up scores.
  2. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).